drugset

drugset / Trial / NCT01631331

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

NCT01631331 ↗

Phase 0 Completed 15 enrolled Stanford University National Cancer Institute (NCI) · collab University Hospitals Cleveland Medical Center · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.

Timeline

Start: 2012-06
Primary completion: 2015-09-17
Completion: 2016-05-31

Outcome

Met primary endpoint

paper Overall, vismodegib reduced the surgical defect area by 27% (95% confidence interval -45.7% to -7.9%; P=.006) from baseline. PMID 24929884 ↗

Publications

Results Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, Oro A, Kim J, Chang AL, Tang JY. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014 Nov;71(5):904-911.e1. doi: 10.1016/j.jaad.2014.05.020. Epub 2014 Jun 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vismodegib	Small molecule	150 mg	Oral

Indications